Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226099 | 0.89 | GPR119 (0.40) | PIK3CDGPR119PIK3CAUSP30PIK3R1 | |
| SCHEMBL5219024 | 0.89 | USP30 (0.37) | PIK3CDGPR119PIK3CAEHMT2PDE4B | |
| SCHEMBL5218998 | 0.89 | GPR119 (0.37) | GPR119PIK3CAEHMT2PDE4BUSP30 | |
| SCHEMBL5219682 | 0.88 | GPR119 (0.39) | GPR119PIK3CAEHMT2USP30SSTR4 | |
| SCHEMBL5216941 | 0.86 | GPR119 (0.38) | GPR119PIK3CAUSP30SSTR4PIK3R1 | |
| SCHEMBL5223395 | 0.85 | PDE4B (0.39) | GPR119PIK3CAEHMT2PDE4BTLR9 | |
| SCHEMBL5219588 | 0.84 | GPR119 (0.41) | PIK3CDGPR119PIK3CAUSP30SSTR4 | |
| SCHEMBL5219779 | 0.84 | GPR119 (0.35) | GPR119PIK3CAEHMT2PDE4BUSP30 | |
| SCHEMBL5222995 | 0.84 | GPR119 (0.35) | GPR119PIK3CAEHMT2PDE4BUSP30 | |
| SCHEMBL5219783 | 0.84 | GPR119 (0.35) | GPR119PIK3CAEHMT2PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641796-B1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | PIK3CD 2686/4885GPR119 17/4885PIK3CA 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.